Nvidia $NVDA has invested $50 million in Recursion Pharmaceuticals $RXRX, an AI drug discovery platform, which has sent its stock up by 78%

Nvidia $NVDA has invested $50 million in Recursion Pharmaceuticals $RXRX, an AI drug discovery platform, which has sent its stock up by 78%.

AI drug discovery has quickly become one of the hottest markets for investment in the startup sector. AI is transforming how new drugs are discovered, enabling faster and cheaper development.

Morgan Stanley expects AI to help develop an additional 50 drugs with an extra $50B in sales in the next decade.

AI in drug discovery will revolutionize the industry. AI is already being used by drugmakers to discover new drugs, speeding up and reducing the cost of the long and expensive drug development process.

The use of AI in drug discovery can lead to the discovery of new drugs that can help cure diseases and improve the quality of life for people.

(Other AI drug discovery platforms, including Exscientia, AbCellera Biologics, and Relay Therapeutics, also rose on the news).